Hypertrophic pulmonary osteoarthropathy: control of pain and symptoms with pamidronate.
This case presents a patient with hypertrophic osteoarthropathy of the lower extremities that developed secondary to congenital cyanotic heart disease. The major clinical manifestation was severe bilateral leg pain. The pain that was debilitating in nature completely resolved following a single administration of 60 mg pamidronate. Hypertrophic osteoarthropathy (HOA) is an acquired, uncommon disorder of obscure etiology. It has been described mainly in association with chronic suppurative pulmonary diseases, bronchogenic carcinoma and lung metastases, cystic fibrosis, and cyanotic congenital malformations of the heart.
Amital
Howard
H
Rheumatology Unit, Department of Radiology and Division of Internal Medicine, Hadassah-Hebrew University School of Medicine, Ein-Karem, POB 12000, 91120 Jerusalem, Israel. amitalh@netvision.net.il
Applbaum
Yaakov H
YH
Vasiliev
Lena
L
Rubinow
Alan
A
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001842:Bone and Bones / Q000000981:diagnostic imaging; D003490:Cyanosis / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D004164:Diphosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D010005:Osteoarthropathy, Secondary Hypertrophic / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D000077268:Pamidronate; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals; D016284:Technetium Tc 99m Pentetate; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D019275:Radiopharmaceuticals; D000077268:Pamidronate; D016284:Technetium Tc 99m Pentetate